192 related articles for article (PubMed ID: 18829308)
1. Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds.
Sabio M; Jones K; Topiol S
Bioorg Med Chem Lett; 2008 Oct; 18(20):5391-5. PubMed ID: 18829308
[TBL] [Abstract][Full Text] [Related]
2. Use of the X-ray structure of the Beta2-adrenergic receptor for drug discovery.
Topiol S; Sabio M
Bioorg Med Chem Lett; 2008 Mar; 18(5):1598-602. PubMed ID: 18243704
[TBL] [Abstract][Full Text] [Related]
3. Molecular dynamics simulations of the effect of the G-protein and diffusible ligands on the β2-adrenergic receptor.
Goetz A; Lanig H; Gmeiner P; Clark T
J Mol Biol; 2011 Dec; 414(4):611-23. PubMed ID: 22037586
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for ligand binding and specificity in adrenergic receptors: implications for GPCR-targeted drug discovery.
Huber T; Menon S; Sakmar TP
Biochemistry; 2008 Oct; 47(42):11013-23. PubMed ID: 18821775
[TBL] [Abstract][Full Text] [Related]
5. Crystallizing thinking about the beta2-adrenergic receptor.
Shukla AK; Sun JP; Lefkowitz RJ
Mol Pharmacol; 2008 May; 73(5):1333-8. PubMed ID: 18239031
[TBL] [Abstract][Full Text] [Related]
6. In silico carborane docking to proteins and potential drug targets.
Calvaresi M; Zerbetto F
J Chem Inf Model; 2011 Aug; 51(8):1882-96. PubMed ID: 21774557
[TBL] [Abstract][Full Text] [Related]
7. Molecular modeling of A1 and A2A adenosine receptors: comparison of rhodopsin- and beta2-adrenergic-based homology models through the docking studies.
Yuzlenko O; Kieć-Kononowicz K
J Comput Chem; 2009 Jan; 30(1):14-32. PubMed ID: 18496794
[TBL] [Abstract][Full Text] [Related]
8. Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6.
Hattori K; Orita M; Toda S; Imanishi M; Itou S; Nakajima Y; Tanabe D; Washizuka K; Araki T; Sakurai M; Matsui S; Imamura E; Ueshima K; Yamamoto T; Yamamoto N; Ishikawa H; Nakano K; Unami N; Hamada K; Matsumura Y; Takamura F
Bioorg Med Chem Lett; 2009 Aug; 19(16):4679-83. PubMed ID: 19608416
[TBL] [Abstract][Full Text] [Related]
9. On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor.
Costanzi S
J Med Chem; 2008 May; 51(10):2907-14. PubMed ID: 18442228
[TBL] [Abstract][Full Text] [Related]
10. Application of Monte Carlo-based receptor ensemble docking to virtual screening for GPCR ligands.
Vilar S; Costanzi S
Methods Enzymol; 2013; 522():263-78. PubMed ID: 23374190
[TBL] [Abstract][Full Text] [Related]
11. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function.
Rosenbaum DM; Cherezov V; Hanson MA; Rasmussen SG; Thian FS; Kobilka TS; Choi HJ; Yao XJ; Weis WI; Stevens RC; Kobilka BK
Science; 2007 Nov; 318(5854):1266-73. PubMed ID: 17962519
[TBL] [Abstract][Full Text] [Related]
12. Insights into signaling from the beta2-adrenergic receptor structure.
Audet M; Bouvier M
Nat Chem Biol; 2008 Jul; 4(7):397-403. PubMed ID: 18560432
[TBL] [Abstract][Full Text] [Related]
13. Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor.
de Graaf C; Rognan D
J Med Chem; 2008 Aug; 51(16):4978-85. PubMed ID: 18680279
[TBL] [Abstract][Full Text] [Related]
14. Betablockers at work: the crystal structure of the beta2-adrenergic receptor.
Hausch F
Angew Chem Int Ed Engl; 2008; 47(18):3314-6. PubMed ID: 18348114
[No Abstract] [Full Text] [Related]
15. Toward the active conformations of rhodopsin and the beta2-adrenergic receptor.
Gouldson PR; Kidley NJ; Bywater RP; Psaroudakis G; Brooks HD; Diaz C; Shire D; Reynolds CA
Proteins; 2004 Jul; 56(1):67-84. PubMed ID: 15162487
[TBL] [Abstract][Full Text] [Related]
16. Recent structural advances of β1 and β2 adrenoceptors yield keys for ligand recognition and drug design.
Soriano-Ursúa MA; Trujillo-Ferrara JG; Correa-Basurto J; Vilar S
J Med Chem; 2013 Nov; 56(21):8207-23. PubMed ID: 23862978
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel inhibitors of Trypanosoma cruzi trans-sialidase from in silico screening.
Neres J; Brewer ML; Ratier L; Botti H; Buschiazzo A; Edwards PN; Mortenson PN; Charlton MH; Alzari PM; Frasch AC; Bryce RA; Douglas KT
Bioorg Med Chem Lett; 2009 Feb; 19(3):589-96. PubMed ID: 19144516
[TBL] [Abstract][Full Text] [Related]
18. Beyond rhodopsin: G protein-coupled receptor structure and modeling incorporating the beta2-adrenergic and adenosine A(2A) crystal structures.
Tebben AJ; Schnur DM
Methods Mol Biol; 2011; 672():359-86. PubMed ID: 20838977
[TBL] [Abstract][Full Text] [Related]
19. Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors.
Mizutani MY; Itai A
J Med Chem; 2004 Sep; 47(20):4818-28. PubMed ID: 15369385
[TBL] [Abstract][Full Text] [Related]
20. Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography.
Wacker D; Fenalti G; Brown MA; Katritch V; Abagyan R; Cherezov V; Stevens RC
J Am Chem Soc; 2010 Aug; 132(33):11443-5. PubMed ID: 20669948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
